`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`MYLAN PHARMACEUTICALS INC.
`
`Petitioner,
`
`RESEARCH CORPORATION TECHNOLOGIES, INC.,
`Patent Owner.
`
`Case No. IPR2016—01101
`
`Patent No. RE 38,551
`
`PATENT OWNER RESEARCH CORPORATION TECHNOLOGIES,
`INC.’S MANDATORY NOTICES UNDER 37 C.F.R. § 42.8
`
`
`
`Patent No. RE 38,551
`
`Case No. IPR2016—01101
`
`Pursuant
`
`to 37 C.F.R.
`
`§ 42.8, Patent Owner Research Corporation
`
`Technologies, Inc. submits the following Mandatory Notices. In accordance with
`
`37 C.F.R. 42.8(a)(2), these Mandatory Notices are being timely filed within 21
`
`days of service of the petition.
`
`A.
`
`Real Party-In-Interest Under 37 C.F.R. § 42.8(b)(1)
`
`The real parties—in—interest are Research Corporation Technologies,
`
`lnc.;
`
`Harris FRC Corporation; UCB, lnc.; UCB Biopharma SPRL; and UCB Pharma
`
`GmbH.
`
`B.
`
`Related Matters Under 37 C.F.R. § 42.8(b)(2)
`
`The Patent Trial and Appeal Board denied an earlier filed Petition for Inter
`
`Partes Review of RE38,551, IPR2014—01126. A second Petition for Inter Partes
`
`Review of RE38,551, IPR2016-00204, was filed on November 23, 2015, and was
`
`instituted on May 23, 2016. A request for ex parte reexamination of RE38,551
`
`(Control No. 90/013,709) was filed on March 25, 2016; a decision whether to grant
`
`the request is due by July 29, 2016.
`
`Patent Owner further identifies the following related judicial proceedings
`
`involving RE38,551:
`
`I Case Caption
`UCB, Inc. et al. v. Teva Pharmaceuticals USA Inc.
`et al., 1:13—cv-01l48—LPS (D. Del)
`UCB, Inc. et al. v. Accord Healthcare Inc. et al.,
`1:l3—cv~01206—LPSLD_.Del.)
`
`I Disposition
`
`closed
`
`pending
`
`
`
`Patent No. RE 38,551
`
`Case No. lPR2016—O1l01
`
`Disposition
`pending, consolidated with
`1:13—cV—()12O6—LPS (D. Del.)_
`pending, consolidated with
`1:l3—cv~O1206-LPS (D. Del.)
`pending, consolidated with
`1:13—cV—0l206—LPS (D. Del.)
`pending, consolidated with
`1:l3—cV~Ol2O6—LPS (D. Del.)
`pending, Consolidated with
`1:13—cv-O1206~LPS (D. Del.)
`closed
`
`.1
`
`pending, consolidated with
`l:13—cV-0l206—LPS (D. Del.)
`closed
`
`Case Caption
`l UCB, Inc. et al. v. Alembic Pharmaceuticals Ltd,
`l:13—cv-Ol207—LPS (D. Del.)
`UCB, Inc. et al. v. Amneal Pharmaceuticals, LLC
`et al., l:13—cv—O1208—LPS(D. Del.)
`UCB, Inc. et al. v. Apotex Corp. et al., l:l3—cV-
`01209-LPS (D. Del.)
`UCB, Inc. et al. v. Aurobindo Pharma Ltd. et al.,
`1:l3—cV—0121O—LPS (D. Del.)
`UCB, Inc. et al. v. Breckenridge Pharmaceutical
`Inc. et al., 1:13—cV—0l211—LPS (D. Deli)
`UCB, Inc. et al. v. Glenmark Generics Inc. USA et
`al., 1:13—CV—01212—LPS (D. Del.)
`UCB, Inc. et al. v. Hetero USA Inc. et al., 1:13—cV— closed
`Ol213—LPS (D. Del.)
`UCB, Inc. et al. v. Mylan Pharmaceuticals Inc. et
`al., 1:13—CV-()1214—LPS (D. Del.)
`UCB, Inc. et al. v. Ranbaxy Laboratories Ltd. et
`al., 1:13~cv—O1215-LPS (D. Del.)
`UCB, Inc. et al. 1/. Sandoz Inc., 1:13-CV—0l216—
`LPS (D. Del.)
`UCB, Inc. et al. v ScieGen Pharmaceuticals Inc. et Closed
`al., l:l3—cv—Ol2l7-LPS (D. Del.)
`UCB, Inc. et al. v Sun Pharma Global FZE et al.,
`l:l3—cv—0l218—LPS
`Del)
`UCB, Inc. et al. v. Watson Laboratories Inc. —
`Florida et al., 1:l3—cV—O1219—LPS (D. Del.)
`UCB, Inc. et al. v. Zydus Pharmaceuticals (USA)
`Inc. et al., 1:13-CV-01220-LPS (D. Del.)
`UCB, Inc. et al. v. Apotex Corp. et al., l:14—cv-
`O0834—LPS (D. Del)
`UCB, Inc. et al. V. Sun Pharma Global FZE et al.,
`1:l3—cv~055l4(N.D.lll.)
`UCB, Inc. et al., V. Zydus Pharmaceuticals (USA),
`Inc. et al., 3:l3—cV~04021 (D.N.J.)
`'
`
`Closed
`
`pending, consolidated with
`1:13-cV—01206—LPS (D. Del.)
`pending, Consolidated with
`1:l3—CV-O1206—LPS (D. Del.)
`pending, consolidated with
`1:13-cV—012O6-LPS (D. De1)_
`pending, consolidated with
`1:l3—CV—0l206—LPS (D. Del.)
`closed
`
`closed
`
`
`
`Patent No. RE 38,551
`
`Case No. IPR2016-01 101
`
`C.
`
`Lead and Back-Up Counsel Under 37 C.F.R. § 42.8(b)(3)
`
`Lead Counsel
`
`Back-Up Counsel
`
`Jennifer L. Robbins (Reg. No. 61,163)
`jrobbins@cov.com
`Postal and Hand—Delivery Address:
`Covington & Burling LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018
`Telephone: (212) 841-1180
`Facsimile: (212) 841-1010
`
`Andrea G. Reister (Reg. No. 36,253)
`areister@cov.com
`
`Postal and Hand-Delivery Address:
`Covington & Burling LLP
`One CityCenter, 850 Tenth Street, NW
`Washington, DC 20001
`Telephone: (202) 662-5141
`Facsimile: (202) 778-5141
`
`Additional Back-Up Counsel
`Enrique D. Longton (Reg. No. 47,304)
`rlongton@cov.com
`Postal and Hand-Delivery Address:
`Covington & Burling LLP
`One CityCenter, 850 Tenth Street, NW
`Washington, DC 20001
`Telephone: (202) 662-5108
`Facsimile: (202) 778-5108
`
`D.
`
`Service Information Under 37 C.F.R. § 42.8(b) (4)
`
`Service information for lead and back-up counsel
`
`is provided in the
`
`designation of lead and back-up counsel, above. Service of any documents via
`
`hand—delivery may be made at the postal mailing address of the respective lead and
`
`back-up counsel designated above.
`
`Patent Owner Reseach Corporation
`
`Technologies, Inc. consents to electronic service by email at the above listed email
`
`addresses of lead and back-up counsel.
`
`
`
`Patent No. RE 38,551
`
`Case No. IPR2016—01101
`
`E.
`
`Power of Attorney
`
`A Power of Attorney to transact all business in the United States Patent &
`
`Trademark Office (“USPTO”)
`
`in connection with the aboVe—referenced Inter
`
`Partes Review from Patent Owner Research Corporation Technologies, Inc. to the
`
`above-designated counsel at Covington & Burling LLP is being filed concurrently
`
`with these Mandatory Notices. The Power of Attorney is accompanied by a
`
`Statement Under 37 C.F.R. § 3.73(b), executed by the Patent Owner.
`
`Date: June 10, 2016
`
`Respectfully submitted,
`
`
`
`Andrea G. Reistr
`Registration No. 36,253
`Jennifer L. Robbins
`
`Registration No. 61,163
`COVINGTON & BURLING LLP
`
`One CityCenter, 850 Tenth Street, NW
`Washington, DC 20001
`(202) 662-6000
`Attorneys for Patent Owner
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6, I hereby certify that on this 10th day of June 2016,
`
`the foregoing Patent Owner Research Corporation Technologies, lnc.’s Mandatory
`
`Notices Under 37 C.F.R. § 42.8 was served by FedEx®, a means at least as fast and
`
`reliable as Priority Mail Express®, on the following counsel of record for
`
`petitioner.
`
`Steven W. Parmelee
`
`Michael T. Rosato
`
`Jad A. Mills
`
`Wilson Sonsini Goodrich & Rosati
`
`701 Fifth Avenue, Suite 5100
`
`Seattle, WA 98104
`
`Date: June 10, 2016
`
`
`3
`3
`/2 ,.z’§r’? ’§../5/{.;£..x
`
`
`
`Andrea G. R61; er, Esq.
`Registration No.: 36,253